NCT00365053: PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery |
|
|
| Completed | 2 | 13 | US | belinostat, PXD101, laboratory biomarker analysis | National Cancer Institute (NCI) | Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma | 03/09 | 03/09 | | |
ETCTN, NCT04340843: Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma |
|
|
| Active, not recruiting | 2 | 32 | US | Belinostat, Beleodaq, PXD 101, PXD101, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Decitabine and Cedazuridine, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inqovi, Guadecitabine, DNMT inhibitor SGI-110, S110, SGI-110, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI | National Cancer Institute (NCI) | Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma | 01/25 | 01/25 | | |
| Completed | 1/2 | 41 | Europe | PXD101, PXD101 (Belinostat), Doxorubicin, Doxorubicin (Adriamycin) | Onxeo, Spectrum Pharmaceuticals, Inc | Dose Escalation: Solid Tumors, MTD: Soft Tissue Sarcomas | 10/12 | 10/12 | | |
